The foundational study behind most hair-specific copper peptide claims is a 2007 paper that isolated hair follicles from human scalp tissue and tested a tripeptide-copper complex on follicle elongation and dermal papilla cell activity in culture. That paper is specifically about AHK-Cu (Ala-His-Lys), a related synthetic copper peptide with follicle-specific research behind it, not GHK-Cu. We've seen it cited correctly as an AHK-Cu study on some sites and incorrectly presented as GHK-Cu evidence on others, sometimes within the same article. Given how visually similar the two compound names are and how often they're discussed together, this mix-up is understandable, but it means a lot of "GHK-Cu grows hair" content is actually describing a different, related compound.

The full detail of that 2007 research, and why AHK-Cu specifically was engineered for follicle biology, is covered in the article on AHK-Cu: the copper peptide designed for hair.

Beyond the AHK-Cu mix-up, we found a specific citation repeated across multiple commercial peptide sites attributing a 2018 Scientific Reports paper on GHK-Cu and Wnt/beta-catenin signalling in hair follicles to an author list that includes a well-known cardiologist with no evident connection to dermatology or hair research. That's a strong signal of a fabricated or AI-generated citation rather than a real paper, and we haven't been able to locate anything matching it in the actual published record.

GHK-Cu's genuinely well-documented activity is in general tissue remodelling: stimulating collagen, elastin, and glycosaminoglycan production, modulating matrix metalloproteinase activity, and supporting angiogenesis (new blood vessel formation), covered in more depth in the article on GHK-Cu and scarring. None of that research was conducted specifically in hair follicles, but the follicle environment, the dermal papilla, the surrounding connective tissue, the capillary network supplying it, is exactly the kind of tissue this general mechanism would plausibly be relevant to. This is a reasonable extension of established biology, not a demonstrated hair-specific effect.

One real, verifiable study is worth mentioning with appropriate caveats. A 2025 report in JAAD International documented outcomes for seven men with androgenetic alopecia who received five monthly sessions combining microneedle-delivered minoxidil, dutasteride, and copper peptides together in a single compounded solution. The combination group showed a larger median improvement in scalp coverage than a previously studied two-drug protocol without copper peptides. This is real data, but it comes with serious limitations: it's a retrospective analysis of seven patients, there was no control arm, the treatment combined three actives at once so copper peptides' individual contribution can't be isolated, and the report doesn't specify whether the copper peptide used was GHK-Cu, AHK-Cu, or a blend.

If hair is the primary goal, AHK-Cu is the compound with dedicated, if still limited, follicle-specific research behind it, which is why it's the active in AmpleLab's hair and scalp serum rather than GHK-Cu. GHK-Cu's case for hair rests on general tissue-remodelling mechanism and biological plausibility rather than dedicated follicle trials of its own, and a meaningful share of the "GHK-Cu grows hair" content circulating online is actually describing AHK-Cu's research, misattributed, or citing sources that don't check out under scrutiny.

This doesn't mean GHK-Cu has no relevance to scalp health at all. Its documented effects on connective tissue remodelling and vascular biology make follicular relevance biologically plausible, but plausibility is not the same thing as direct evidence, and its safety profile remains the most established of any copper peptide. Part of the reason GHK-Cu became associated with hair in the first place is simply timing: it was the first copper peptide to gain widespread attention, through decades of skin and wound-healing research, long before AHK-Cu entered the conversation as a more narrowly hair-focused compound. That head start likely explains why GHK-Cu's name gets attached to hair claims that, on closer inspection, belong to AHK-Cu instead. For a direct comparison of where each compound's evidence is strongest, see GHK-Cu vs AHK-Cu.

The Pyo et al. paper is specifically about AHK-Cu, included here because it's the study most frequently, and often incorrectly, cited as GHK-Cu evidence elsewhere online. The Kuceki et al. study is a small, uncontrolled, three-drug combination report and should not be read as evidence for copper peptides, let alone GHK-Cu specifically, in isolation.

This article is provided for educational purposes. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition. Consult a qualified healthcare professional for advice on hair loss treatment.

AmpleLab.